Robust financial markets continue to fuel the industry despite gloom over the COVID-19 pandemic, with Relay Therapeutics Inc. pricing its upsized, 20 million-share IPO at $20 per unit to reap $400 million.
Courtesy of a $50 million series A, Adagio Therapeutics Inc. will join a raft of other companies attempting to end the COVID-19 pandemic with antibodies.
HONG KONG – Chinese eye disease specialist Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $32 million in a series A financing round to advance its lead program, ARVN-001 (triamcinolone acetonide suprachoroidal injectable suspension), for treating macular edema associated with uveitis and to bolster its R&D.
HONG KONG – Chinese biotech giant Beigene Ltd. launched a $2.08 billion registered direct offering this week, the largest offering of its kind ever recorded globally. Beigene executives said net proceeds will primarily be used for general corporate purposes such as R&D for existing or new drugs in the pipeline.
BEIJING – Beijing-based Immunotech Biopharm Ltd. made a strong debut as the first pre-revenue cellular immunotherapy firm to trade on the Hong Kong Stock Exchange (HKEX), raising $142 million via its IPO. Trading under the ticker 6978, the company’s share price closed at HK$15.48 (US$2) on July 10, up 40.7% from its offer price at HK$11.
Following a brisk quarter of healthy biopharma dealmaking driven in part by New York-based Blackstone Group Inc., the global investment giant has revealed that its Life Sciences Fund V has closed with $4.6 billion of capital commitments, making it what the firm said is the largest life sciences private fund raised to date.
RSS
